Dostarlimab
About
Therapy type: Immunotherapy
Therapy strategy: PD-1/PD-L1 inhibition
Mappings
NCI Thesaurus: Dostarlimab (coding:ncit:C126799)
RxNorm: dostarlimab (coding:rxcui:2539967, coding:omop:1536789)
SNOMED: Dostarlimab (coding:sctid:1156877005, coding:omop:608113)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) HSE (1) | dMMR | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| FDA (1) HSE (1) | MSI-H | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| EMA (1) FDA (1) | dMMR | Endometrial Carcinoma | Dostarlimab | |
| FDA (1) | dMMR | Any solid tumor | Dostarlimab | |
| EMA (1) | MSI-H | Endometrial Carcinoma | Dostarlimab |